Home > Drugs A – Z > Trospium (By mouth)

Trospium (By mouth)

Treats symptoms of an overactive bladder.

What works?

Learn more about the effects of these drugs. The most reliable research is summed up for you in our featured article.

Trospium is used to treat the symptoms of an overactive bladder, such as a frequent need to urinate or incontinence (loss of bladder control). It helps to relax the muscles in the bladder and reduce the daily episodes of incontinence. Trospium is a urinary antispasmodic agent. This medicine is available only with your doctor's prescription… Read more
Brand names include
Sanctura, Sanctura XR
Drug classes About this
Urinary Antispasmodic

What works? Research summarized

Evidence reviews

Mirabegron Extended-Release Tablets (Myrbetriq): Treatment of Overactive Bladder (OAB) with Symptoms of Urgency, Urgency Incontinence and Urinary Frequency [Internet]

Overactive bladder (OAB) is a chronic condition of the lower urinary tract characterized by symptoms of urinary urgency, with or without urgency incontinence, usually with urinary frequency and nocturia. Mirabegron is selective beta 3-adrenoceptor agonist available as a 25 mg and 50 mg extended-release (ER) tablet. It is approved for the treatment of OAB with symptoms of urgency, urgency incontinence, and urinary frequency. The manufacturer has requested that mirabegron be listed in a manner similar to other second-line OAB drugs. The objective of this report is to perform a systematic review of the beneficial and harmful effects of mirabegron ER (Myrbetriq) for the treatment of OAB.

Drug Class Review: Agents for Overactive Bladder: Final Report Update 4 [Internet]

Overactive bladder is defined by the International Continence Society as a syndrome of urinary frequency and urgency, with or without urge incontinence, appearing in the absence of local pathological factors. Treatment of overactive bladder syndrome first requires a clear diagnosis. In patients with incontinence, multiple forms can be present and it is important to determine which form is dominant. Non-pharmacologic, non-surgical treatment consists of behavioral training (prompted voiding, bladder training, pelvic muscle rehabilitation), transcutaneous electrical nerve stimulation, catheterization, and use of absorbent pads. Pharmacologic treatment for overactive bladder syndrome includes darifenacin, flavoxate hydrochloride, hyoscyamine, oxybutynin chloride, tolterodine tartrate, trospium chloride, scopolamine transdermal, and solifenacin succinate. The purpose of this systematic review is to compare the benefits and harms of drugs used to treat overactive bladder syndrome.

Urinary Incontinence in Women: The Management of Urinary Incontinence in Women

This guidance is a partial update of National Institute for Health and Care Excellence (NICE) clinical guideline 40 (published October 2006) and will replace it.

See all (19)

Summaries for consumers

Comparing Drugs for Overactive Bladder Syndrome

How do anticholinergics compare in treating overactive bladder syndrome?

Non-surgical Treatments for Urinary Incontinence: A Review of the Research for Women

The information in this summary is from a report that reviewed 905 studies between January 1990 and December 2011 on treatments without surgery for urinary incontinence. You can use the information from research to understand what is known about the possible benefits and side effects of each treatment option. This information will help you talk with your doctor about what option may be best for you.

Mirabegron (Betmiga) for overactive bladder: Overview

Mirabegron (trade name: Betmiga) has been approved in Germany since December 2012 for the treatment of overactive bladder in adults.

See all (5)

PubMed Health Blog...

read all...